A type of aggressive, treatment-resistant brain tumor has a distinct population of immune cells that support its growth, according to new research.

A single-center study suggests the surgery is safe and effective even when tumors are large or located in high-risk areas.

The shortage of generic chemotherapy drugs cisplatin and carboplatin that began in early 2023 did not increase short-term ...

Lung cancer remains a leading cause of cancer death globally, with a significant rise in cases among non-smokers attributed ...

After their advanced kidney tumors were surgically removed, nine patients were protected from the cancer returning thanks to ...

Study results show that genetic sensitivity to stress was linked to a 49% higher risk of lung cancer in people of European ...

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.

Serplulimab is the world's first anti-PD-1 monoclonal antibody (mAb) approved for first-line treatment of ES-SCLC Serplulimab is the first and only anti-PD-1 mAb approved in the European Union (EU) ...

The leading Triple Negative Breast Cancer Companies such as Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 ...

In resectable, locally advanced esophageal squamous cell carcinoma, neoadjuvant Tyvyt plus chemoradiotherapy led to an ...

Initiation of Phase 1/2 combination trial with PYX-201, an extracellular ADC targeting Extradomain-B Fibronectin (EDB+FN) and Merck’s KEYTRUDA® ...

Bladder cancer often begins with subtle symptoms that are easy to overlook. The most common early sign is blood in the urine, a condition known as hematuria. In many cases, the blood may not always be ...